TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10477639

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (human) (FSH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Thrombin-soaked gelatin sponge (TSG)
Number of subjects: 47
Study: 8934061

Group type: EXPERIMENTAL
Intervention: Nomegestrol subdermal contraceptive implant (Uniplant)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Intrauterine contraceptive device (CuT 380A)
Number of subjects: 240
Study: 1877516

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 181

Group type: COMPARATOR
Intervention: Caffeinated coffee (control)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (discontinuation)
Number of subjects: 181
Study: 6401357

Group type: EXPERIMENTAL
Intervention: flexed position
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: extended position
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: upright position
Number of subjects: 17
Study: 30837021

Group type: EXPERIMENTAL
Intervention: Eye tracking measure
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: No neglect symptoms
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined egocentric and allocentric neglect
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Allocentric or egocentric neglect
Number of subjects: 20
Study: 29698019

Group type: EXPERIMENTAL
Intervention: Similar Age Mixed Gender (SAMG) exercise group
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Similar Age Same Gender (SASG) exercise group
Number of subjects: 627

Group type: COMPARATOR
Intervention: Standard Mixed Age Mixed Gender (MAMG) exercise group
Number of subjects: 627
Study: 26493304

Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg with morphine 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Prasugrel 60 mg with placebo
Number of subjects: 12
Study: 24906437

Group type: EXPERIMENTAL
Intervention: Tapentadol ER (50-250 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine SR (20-140 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 50
Study: 22854406

Group type: COMPARATOR
Intervention: Pure ß-carotene in oil (0.5 mg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Golden Rice ß-carotene (0.6 mg)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Spinach ß-carotene (1.4 mg)
Number of subjects: 68
Study: 19736632

Group type: EXPERIMENTAL
Intervention: CO2 treatment for 18 consecutive days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 62
Study: 17763050

Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and addiction behaviors with patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and health promotion counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and addiction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician discussion of substance use and addiction behaviors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addiction-oriented practice style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addressing substance use and smoking
Number of subjects: 0
Study: 15673130

Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current blood pressure management targets
Number of subjects: 0
Study: 11806476

Group type: EXPERIMENTAL
Intervention: Braun Oral-B D17 power toothbrush
Number of subjects: 110

Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 110
Study: 9488498

Group type: EXPERIMENTAL
Intervention: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with low L-NMMA
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Histamine infusion (0.16 microg/kg/min) after 30 minutes of pretreatment with high L-NMMA
Number of subjects: 9

Group type: COMPARATOR
Intervention: Histamine infusion alone (no L-NMMA pretreatment)
Number of subjects: 9
Study: 7851263

Group type: EXPERIMENTAL
Intervention: Intensified conventional treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: Regular treatment
Number of subjects: 96
Study: 3386328

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (three intravenous dose levels)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 4
Study: 31785390

Group type: EXPERIMENTAL
Intervention: C‐ACT (porcine-derived collagen-augmented chondrogenesis technique)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Microfracture (control group)
Number of subjects: 100
Study: 30274344

Group type: EXPERIMENTAL
Intervention: Pulse-based diet
Number of subjects: 95
Study: 28969702

Group type: EXPERIMENTAL
Intervention: Crowdsourcing intervention for HIV test promotion
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Conventional campaigns
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Crowdsourcing intervention
Number of subjects: 1280
Study: 26428734

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum HY7714 (1 × 10(10) CFU/day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 23352812

Group type: EXPERIMENTAL
Intervention: Tilting embryo culture system (TECS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control static culture system
Number of subjects: 32
Study: 21168015

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting + reduction annuloplasty
Number of subjects: 75
Study: 19633578

Group type: EXPERIMENTAL
Intervention: Multinutrient fortifier added to human milk (n=19)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Human milk alone (n=20)
Number of subjects: 39
Study: 16969617

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy (FH)
Number of subjects: 50
Study: 12751804

Group type: EXPERIMENTAL
Intervention: Active oddball task (rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive single-stimulus task (humans)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P3 component (rats)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P3 component (humans)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison of P3 components between species
Number of subjects: 0
Study: 11097105

Group type: EXPERIMENTAL
Intervention: 1995 knowledge of lipid values
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 1995 belief in hyperlipidaemia as a cause of CHD
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 1995 belief in reduction of hyperlipidaemia reducing cardiovascular risk
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: 1995 belief in reduction of hypertension reducing cardiovascular risk
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Expectation of doctors knowing about smoking habits
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Expectation of doctors knowing about drinking habits
Number of subjects: 1000
Study: 9075669

Group type: EXPERIMENTAL
Intervention: Spironolactone 225 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8416267

Group type: EXPERIMENTAL
Intervention: Low-dose isotretinoin (0.5 mg per kilogram per day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Beta carotene (30 mg per day)
Number of subjects: 59
Study: 2429631

Group type: EXPERIMENTAL
Intervention: surgery + DTIC
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: surgery + BCG
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: surgery + DTIC + BCG
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: surgery + poly‐U‐A
Number of subjects: 1058

Group type: EXPERIMENTAL
Intervention: surgery + vinblastine/bleomycine/cisplatinum
Number of subjects: 1058

Group type: COMPARATOR
Intervention: surgery
Number of subjects: 1058
Study: 30796508

Group type: EXPERIMENTAL
Intervention: 800 mg phytosomal curcumin (Curserin®: 200 mg curcumin, 120 mg phosphatidylserine, 480 mg phosphatidylcholine and 8 mg piperine from Piper nigrum L. dry extract) for 8 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 800 mg phytosomal curcumin (Curserin®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 29406428

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) for 24 weeks
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) and antiretroviral therapy (ART)
Number of subjects: 426
Study: 26523653

Group type: EXPERIMENTAL
Intervention: Telmisartan (160 mg daily for 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 10
Study: 23733256

Group type: EXPERIMENTAL
Intervention: 1-year supervised lifestyle intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (routine lifestyle counselling)
Number of subjects: 83
Study: 23154393

Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 238

Group type: COMPARATOR
Intervention: No axillary dissection
Number of subjects: 238
Study: 20142024

Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP levels measured in pg/mL using the Elecsys proBNP assay (Roche)
Number of subjects: 3562

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of baseline characteristics
Number of subjects: 3562
Study: 17969365

Group type: EXPERIMENTAL
Intervention: pioglitazone
Number of subjects: 0
Study: 15659491

Group type: EXPERIMENTAL
Intervention: 250 mg oral gefitinib daily continuously
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 500 mg oral gefitinib daily continuously
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study: 12516646

Group type: EXPERIMENTAL
Intervention: Early loading of machined-surface Brånemark implants in healed bone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Early loading of machined-surface Brånemark implants in fresh extraction sites
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prostheses installed in fresh extraction sites
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Functional loading of implants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Marginal bone level measurements
Number of subjects: 36
Study: 9704783

Group type: EXPERIMENTAL
Intervention: Length of initial hospital stay > 48 hours
Number of subjects: 4323

Group type: EXPERIMENTAL
Intervention: Home care visits
Number of subjects: 4323

Group type: COMPARATOR
Intervention: Length of initial hospital stay < or = 24 hours
Number of subjects: 4323

Group type: COMPARATOR
Intervention: Length of initial hospital stay 25 to 48 hours
Number of subjects: 4323

Group type: COMPARATOR
Intervention: Maternal factors (preeclampsia, preterm delivery, instrument delivery)
Number of subjects: 4323

Group type: COMPARATOR
Intervention: Length of initial hospital stay
Number of subjects: 4323
Study: 8556789

Group type: EXPERIMENTAL
Intervention: Artemether (Art) 6 mg/kg followed by repeated dosing every 15 days for 3 times.
Number of subjects: 741

Group type: COMPARATOR
Intervention: Placebo (starch) given at the same time as Art group.
Number of subjects: 741

Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Artemether (Art)
Number of subjects: 741
Study: 2399780

Group type: EXPERIMENTAL
Intervention: Labetalol (0.25 mg/kg in divided doses, followed by 0.50 mg/kg until blood pressure < 160/90 mmHg or total dose of 300 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sodium nitroprusside (infusion starting at 0.5 micrograms/kg/min, titrated up to 6.0 micrograms/kg/min)
Number of subjects: 19
Study: 103378

Group type: EXPERIMENTAL
Intervention: Whole-food supplementation (Complan)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 50
Study: 31577104

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement treatment
Number of subjects: 32
Study: 28375803

Group type: COMPARATOR
Intervention: Physiologic saline as placebo (Group 1, n=193)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: First-generation cephalosporin (cefazolin; 1 g) (Group 2, n=191)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Second-generation cephalosporin (cefuroksim aksetil; 750 mg) (Group 3, n=186)
Number of subjects: 570
Study: 24848637

Group type: EXPERIMENTAL
Intervention: Passive exposure to e-cigarette cue
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Passive exposure to combustible cigarette cue
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control cue (drinking bottled water)
Number of subjects: 60
Study: 23623039

Group type: EXPERIMENTAL
Intervention: Colonoscopy
Number of subjects: 5059
Study: 21221990

Group type: EXPERIMENTAL
Intervention: Resistance exercise condition (REC) - 30 incline leg presses conducted during two sessions at 48 and 24 hours prior to IET.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control condition (CC) - subjects refrained from strenuous exercise for 2 days prior to IET.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Resistance exercise condition (REC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Resistance exercise condition (REC) and Control condition (CC)
Number of subjects: 6
Study: 19721138

Group type: EXPERIMENTAL
Intervention: Locked intramedullary nailing (IMN)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dynamic compression plating (DCP)
Number of subjects: 32
Study: 17199538

Group type: EXPERIMENTAL
Intervention: Collagen bioabsorbable membrane
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bone graft alone
Number of subjects: 25
Study: 15741212

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 600

Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 600
Study: 12120421

Group type: EXPERIMENTAL
Intervention: Diets with a lower percentage of calories from fat
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diets with fat consumption within the range of 18-40% of energy
Number of subjects: 0
Study: 12090591

Group type: EXPERIMENTAL
Intervention: 3.75 mg of leuprorelin acetate depot for 8 weeks
Number of subjects: 34
Study: 8947452

Group type: EXPERIMENTAL
Intervention: CarboMedics valve implantation (CM)
Number of subjects: 326

Group type: COMPARATOR
Intervention: St. Jude Medical valve implantation (SJ)
Number of subjects: 326
Study: 1932607

Group type: EXPERIMENTAL
Intervention: Ansaid (film‐coated 100 mg tablet)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Froben (sugar‐coated 100 mg tablet)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: S-configuration of flurbiprofen (Froben)
Number of subjects: 23

Group type: COMPARATOR
Intervention: S-configuration of flurbiprofen (Ansaid)
Number of subjects: 23
Study: 7242963

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide (in association with potassium canrenoate)
Number of subjects: 0
Study: 31536994

Group type: EXPERIMENTAL
Intervention: Serum bicarbonate levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metabolic acidosis prevalence
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bicarbonate levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: eGFR levels
Number of subjects: 90
Study: 28705885

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 (higher levels) in Study A
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 (higher levels) in Study B
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 in Study A
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Fibroblast growth factor 23 quartile 4 in Study B
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Addition of fibroblast growth factor 23 to a model of annualized decline in eGFR≥3.0 ml/min per 1.73 m²
Number of subjects: 1002
Study: 26562604

Group type: EXPERIMENTAL
Intervention: 40 mg/dl (low)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: 65 mg/dl (moderate)
Number of subjects: 94

Group type: COMPARATOR
Intervention: 0 mg/dl (placebo)
Number of subjects: 94
Study: 23800483

Group type: EXPERIMENTAL
Intervention: Multifamily psychoeducational psychotherapy (MF‐PEP)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 165
Study: 21131295

Group type: EXPERIMENTAL
Intervention: Ultrasonography and mammography (intervention group)
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Mammography only (control group)
Number of subjects: 100000
Study: 19143752

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus cream 1% (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Betamethasone cream 0.1% (n = 35)
Number of subjects: 70
Study: 17500625

Group type: EXPERIMENTAL
Intervention: Exercise intervention (details not specified)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Self-efficacy and affect at Year 2
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Original treatment condition
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Covariance modeling analyses
Number of subjects: 174
Study: 15024982

Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine combined with Pneumo 23 and Avaxim vaccines
Number of subjects: 755

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as those not receiving the combined vaccines)
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine
Number of subjects: 755
Study: 12033987

Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg once daily
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily
Number of subjects: 891

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 891
Study: 9834800

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.15 mg.kg‐1 (MIV 15)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mivacurium 0.25 mg.kg‐1 (MIV 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium 0.3 mg.kg‐1 (ATR 30)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg.kg‐1 (ATR 50)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.06 mg.kg‐1 (VEC 06)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg.kg‐1 (VEC 10)
Number of subjects: 50
Study: 8616117

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 and Cyclophosphamide 1200 mg/m2
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cisplatin 80 mg/m2 and Cyclophosphamide 900 mg/m2
Number of subjects: 105
Study: 2748870

Group type: EXPERIMENTAL
Intervention: Apomorphine (Apo) HCl 0.25, 0.5, 0.75, and 1.0 mg sc
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Apomorphine (Apo) HCl
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bromocriptine (open trial)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Apomorphine (Apo) HCl 3.5, 5.0, 7.0, and 10.5 ug/kg sc
Number of subjects: 28
Study: 371030

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31808659

Group type: COMPARATOR
Intervention: Ischemic preconditioning (IPC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 120
Study: 31426703

Group type: EXPERIMENTAL
Intervention: Interarytenoid injection augmentation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Preoperative Penetration‐Aspiration Scale scores
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative Penetration‐Aspiration Scale scores
Number of subjects: 30
Study: 28202370

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing & PRP injection/gel application (study group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Closed intramedullary nailing & PRP injection (subgroup A1)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Open intramedullary nailing & PRP gel with fibrin membrane (subgroup A2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Closed intramedullary nailing (subgroup B1)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Open intramedullary nailing (subgroup B2)
Number of subjects: 72
Study: 26096484

Group type: EXPERIMENTAL
Intervention: Epidural injections of corticosteroids with lidocaine
Number of subjects: 400

Group type: COMPARATOR
Intervention: Lidocaine only
Number of subjects: 400
Study: 23286421

Group type: EXPERIMENTAL
Intervention: Kung Fu training for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-exercise intervention
Number of subjects: 0
Study: 21970138

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 0.2 ml/kg levobupivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Caudal block (CB) with 1 ml/kg levobupivacaine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Caudal block (CB)
Number of subjects: 70
Study: 19280083

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vocational Service
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IPS and Vocational Service
Number of subjects: 48
Study: 16400054

Group type: EXPERIMENTAL
Intervention: Phenylalanine intake of 48 mg x kg(‐1) x d(‐1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Graded intakes of phenylalanine (5, 10, 15, 25, 35, 45, 60, and 70 mg x kg(‐1) x d(‐1))
Number of subjects: 5
Study: 15063762

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms in IL4, IL8RB, IL10RA, PRL, ADA, NFKB1, GRAP2, CABIN1, IFNAR2, IFI27, IFI41, TNFRSF1A, ALDOB, AP1B1, SULT2B1, EGF, EGFR, TGFB1, LTBP2, and CD4
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms in IL1B, IL1RL1, IL2RB, IL12RB1, IL18R1, STAT5A, GRAP2, CABIN1, IFNAR1, Mx1, BMP8, FGL1, LTBP2, CD34, and CD80
Number of subjects: 238
Study: 11284803

Group type: EXPERIMENTAL
Intervention: 5 mg levocetirizine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 10 mg cetirizine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 5 mg dextrocetirizine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 24
Study: 9815721

Group type: EXPERIMENTAL
Intervention: LSF, 1.5 mg/kg i.v. bolus every 6 h during IL-2 therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo every 6 h during IL-2 therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: LSF
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53